OneSource Specialty Pharma Limited has formally withdrawn its credit ratings from CareEdge Ratings as part of a strategic review of its external rating arrangements. The company announced this development to stock exchanges on March 05, 2026, under regulatory disclosure requirements.

Rating Withdrawal Details

CareEdge Ratings has reaffirmed and withdrawn outstanding ratings at the request of OneSource Specialty Pharma Limited . The rating action covers multiple facilities and instruments:

The rating agency specifically withdrew the outstanding rating assigned to the non-convertible debenture of ₹100 crore (ISIN: INE013P07010) as the instrument has been fully repaid by the company.

Existing Rating Framework

Despite the CareEdge withdrawal, OneSource Specialty Pharma maintains its credit rating relationship with India Ratings & Research. The company holds a rating of 'IND A- ; Positive' from India Ratings, which was reaffirmed in December 2025. This rating remains active and provides continued external assessment of the company's creditworthiness.

Business Profile and Recent Performance

OneSource Specialty Pharma operates as a fully integrated, multi-modality specialty pharmaceutical Contract Development and Manufacturing Organisation (CDMO). The company focuses on developing and manufacturing Drug Device Combinations (DDC), biologics, sterile injectables, and oral technologies including soft gelatin capsules.

The company's recent financial performance shows significant scale expansion following strategic mergers. In FY25, OneSource reported total operating income of ₹1,445 crore compared to ₹173 crore in FY24, reflecting the integration of acquired businesses. However, the company experienced some challenges in 9MFY26, reporting total operating income of ₹993 crore with an PBILDT margin of 21.37%.

Manufacturing Capabilities

OneSource operates five manufacturing facilities in Bengaluru with comprehensive regulatory accreditations. The facilities have approvals from major global regulatory bodies including USFDA, EMA, Health Canada, ANVISA, and other international agencies. The company has installed capacity to produce over 100 million injectable doses, 2.4 billion soft gelatin capsules, and 40 million cartridges for Drug Device Combinations.

Strategic Rationale

The company stated that the rating withdrawal is part of its periodic review and rationalisation of external credit ratings. This strategic decision allows OneSource to streamline its rating arrangements while maintaining necessary credit assessment through its relationship with India Ratings & Research. The withdrawal was executed with proper regulatory compliance, including obtaining No Objection Certificates from relevant lenders.

Source: None/Company/INE013P01021/481f8751-cbdd-4ab8-98bd-3bfc8ce9d566.pdf

OneSource Specialty Pharma Limited has announced its participation in the Investec India Promoter & Founder Conference 2026, scheduled to take place on March 09, 2026 in Mumbai. The company informed stock exchanges about this investor engagement activity through a regulatory filing dated March 04, 2026.

Conference Participation Details

The pharmaceutical company's representatives will participate in the conference as part of their regular investor engagement activities. The announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Discussion Topics and Compliance

During the conference interactions, OneSource Specialty Pharma's representatives will discuss publicly available information with investors and stakeholders. The discussions will focus on several key areas:

• Business overview and current operations
• Strategic initiatives and future plans
• Industry trends and market dynamics
• Growth outlook and opportunities

The company has specifically noted that no unpublished price sensitive information (UPSI) will be shared during these interactions, ensuring full compliance with regulatory guidelines and maintaining transparency standards.

Regulatory Communication

The formal intimation was signed by Trisha A, Company Secretary and Compliance Officer (Membership Number: A47635), and communicated to both major stock exchanges where the company is listed. The filing serves as an official record of the company's participation in this investor engagement activity, maintaining adherence to disclosure requirements under SEBI regulations.